Loading
A phase 3 trial of Sacituzumab tirumotecan, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients is a phase 3 interventional study registered as NCT05870319 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 376 participants enrolled, started 2023-06-26 and due to reach its primary completion in 2024-07-11. Interventions recorded: SKB264, Pemetrexed, Carboplatin, Cisplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Pemetrexed, Small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Carboplatin, Small-cell lung cancer.
Shares Sacituzumab tirumotecan, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.